CurrentCapital BluecrossPolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism

Diagnostic Testing of Iron Homeostasis and Metabolism

Defines coverage criteria for laboratory tests of iron status (e.g., serum ferritin, transferrin saturation) and specifies tests that are not covered (e.g., hepcidin, GlycA). Applies to Capital BlueCross members subject to their benefit coverage.

Policy Summary

PayerCapital Bluecross

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism

Change TypeMinor/No material change

Effective Date

Next Review DateMay 1, 2026

Key ActionOrder serum ferritin or transferrin saturation only when indications listed in the coverage criteria are met and document clinical rationale in the record.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1/momax ferritin testing frequency

q3wferritin freq (overload)

not coveredhepcidin testing

not coveredGlycA testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ferritin threshold (ID)

8listed procedure codes

Coverage Criteria for Iron Testing

Covered indications for ferritin and transferrin testing

Measurement of serum ferritin and transferrin/transferrin saturation meets coverage when ANY of the following indications are met. Frequency limits noted where applicable.

ANY of the following

Measurement of serum ferritin for individuals with anemia (no more than one test per month unless otherwise specified).
Measurement of serum ferritin once every three weeks for individuals with an iron overload disorder.
Measurement of serum ferritin for individuals with symptoms of hemochromatosis (see Note 1).
Measurement of serum ferritin for individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH) (see Note 2).
Measurement of serum ferritin for evaluation of individuals with liver disease.
Measurement of serum ferritin for evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease.
Measurement of serum ferritin in males with secondary hypogonadism.
Chronic kidney disease monitoring
- One test every three months if the individual is not receiving dialysis.
- One test every month if the individual is receiving dialysis.
Measurement of serum ferritin for individuals on iron therapy (monitoring).
Measurement of serum ferritin for individuals with restless legs syndrome or periodic limb movement disorder.
Measurement of transferrin saturation for the evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1).
Measurement of transferrin saturation for the evaluation of iron overload in individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH) (see Note 2).
Measurement of transferrin saturation for the evaluation of iron deficiency anemia.
Measurement of transferrin saturation for individuals with restless legs syndrome or periodic limb movement disorder.

ANY of the following

Measurement of ferritin or transferrin (including transferrin saturation) outside the indications listed above does NOT meet coverage criteria.
Serum hepcidin testing, including immunoassays, does NOT meet coverage criteria.
Use of GlycA testing to measure or monitor transferrin or other glycosylated proteins does NOT meet coverage criteria.

ANY of the following

Evidence-based diagnostic and management testing strategies are supported when contextual guideline criteria are met (for example: ICCAMS, KDIGO, ASH, WHO, ECCO, AGA recommendations on thresholds and monitoring intervals).
Interpretation considerations: ferritin thresholds vary by clinical context (eg, ferritin <30 µg/L sensitive for iron deficiency in general; higher thresholds used in inflammatory states or specific conditions — see guideline references).
When ferritin is 100-300 µg/L in patients with inflammatory conditions, TSAT <20% may be required to confirm iron deficiency; diagnostic and monitoring strategies should follow specialty guideline recommendations.

ANY of the following

Selected guideline diagnostic thresholds and monitoring recommendations: WHO ferritin cut-offs by age and inflammation status; ASH recommendations for frequent ferritin monitoring during iron chelation (every 3-6 weeks) to calculate running averages; KDIGO recommendations for testing frequency in CKD (every 3 months for non-dialysis, monthly for hemodialysis) and withholding iron if ferritin ≥700 ng/mL or TSAT ≥40%; ECCO monitoring intervals for IBD patients (every 3-12 months depending on activity).

ANY of the following

Monitoring during therapy: follow guideline-recommended intervals — e.g., reassess hemoglobin 2-4 weeks after initiating oral iron in moderate-severe anemia; ferritin re-check 3-6 months after normalization of hemoglobin or after initiation of iron supplementation in non-anemic patients; for iron chelation therapy monitor ferritin frequently (every 3-6 weeks) to assess trends.

ANY of the following

Diagnostic use of ferritin alone to screen asymptomatic individuals for iron deficiency has insufficient evidence and is not supported as routine screening; USPSTF considers evidence insufficient to recommend routine screening for iron deficiency anemia in asymptomatic pregnant individuals (grade I).

ANY of the following

Imaging indications (PKAN): No specific coverage criteria for routine ferritin/transferrin testing in neurodegeneration with brain iron accumulation (NBIA) broadly; the only NBIA guideline identified pertains to pantothenate kinase-associated neurodegeneration (PKAN) where diagnostic imaging (eg, MRI) is the primary modality. Ferritin testing is not established as a routine diagnostic for PKAN in the absence of clinical indications; individualized symptomatic evaluation is recommended.

ANY of the following

No coverage criteria in this document portion: placeholder for topics not addressed here (no top-level coverage rules beyond those listed).

Procedure Codes and Diagnostic Thresholds

Applicable CPT/HCPCS procedure codes section referencedmixed

No codes listed

Listed Procedure Codesmixed

82728	Ferritin
83540	Iron
83550	Iron binding capacity
84466	Transferrin
84999	Unlisted chemistry procedure
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (Proprietary test: GlycA; Lab/Manufacturer: Laboratory Corporation of America)
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma (Proprietary test: Intrinsic Hepcidin IDx ™; Lab/Manufacturer: IntrinsicDx)

No codes listed in these chunksmixed

No codes listed

Serum ferritin diagnostic thresholds — inv-18

Low serum ferritin (general)Serum ferritin <30 µg/L is a sensitive and specific indicator of iron deficiency.

Inflammatory/comorbid conditions (CHF, CKD, IBD)In congestive heart failure, chronic kidney disease, and inflammatory bowel disease a serum ferritin <100 µg/L OR TSAT <20% can be considered diagnostic of iron deficiency.

Ferritin 100–300 µg/LIf serum ferritin is 100–300 µg/L then TSAT <20% is required to confirm iron deficiency.

Serum ferritin thresholds — inv-19

WHO age- and context-specific cutoffsWHO recommends cut-off ferritin levels by age and inflammation status (eg, <12 µg/L in infants/young children; <15 µg/L in healthy adults; higher cutoffs in infection/inflammation).

Provider Requirements, Documentation, and Denial Triggers

Documentation Required

Testing frequency and required documentation

Measurement of serum ferritin is limited to no more than one test per month unless otherwise specified by the indications listed in this policy (see exceptions for iron overload, dialysis, and other specific conditions). Documentation must support that testing falls within the listed indications (e.g., anemia, iron overload, symptoms of hemochromatosis, family history, liver disease, HLH/Still Disease, hypogonadism, iron therapy monitoring, restless legs syndrome/PLMD, or CKD-specific frequency).

Limit: ≤1 ferritin test per month unless an exception applies (see policy indications).
Exceptions: ferritin every 3 weeks for iron overload; CKD non-dialysis: every 3 months; CKD dialysis: monthly.

Prior Authorization

Oral iron trial preferred; IV iron formulation preference and documentation

Oral iron therapy given every other day (and adjuncts such as vitamin C to enhance absorption) is the preferred initial approach for iron deficiency in most patients. IV iron is recommended when oral iron is not tolerated, when ferritin does not improve after an adequate oral iron trial, or when absorption is likely impaired. When IV iron is used, prefer formulations that replace iron deficits in 1–2 infusions; justify use of formulations that require more than two infusions. Document the oral iron trial, tolerance, dosing regimen, duration, and ferritin/iron response when requesting IV iron.

Key Definitions and Biomarker Descriptions

Serum ferritin (SF) definition — inv-39

DefinitionSerum ferritin (SF) is the circulating form of the intracellular iron storage protein ferritin and reflects body iron stores.

Acute-phase reactantFerritin is an acute-phase/reactant that increases with inflammation, liver disease, malignancy, and oxidative stress, which can confound interpretation of iron status.

Biologic roleFerritin stores iron intracellularly and has ferroxidase activity; serum ferritin is primarily derived from macrophages via nonclassical secretion pathways.

Hepcidin — inv-40

DefinitionHepcidin is a small peptide hormone encoded by HAMP that regulates systemic iron by binding to ferroportin and inducing its internalization and degradation.

Physiologic effect

Required Biomarkers for Assessment

Ferritin, TSAT, TIBC — inv-50

Required biomarker setFerritin, transferrin saturation (TSAT), and total iron-binding capacity (TIBC) are the core laboratory tests required to evaluate iron status, particularly for monitoring during ESA therapy and initial anemia evaluation.

Context of useThese tests are recommended as baseline and periodic monitoring during ESA treatment and for evaluation of iron deficiency or overload across multiple guidelines (ASCO/ASH, KDIGO, ICCAMS).

Sampling considerationsTSAT is calculated from serum iron and TIBC; timing of sample and withholding iron/chelators may be necessary per guidelines for accurate interpretation.

Background on Iron Homeostasis

Iron homeostasis is tightly regulated to maintain physiologic function. Key processes include intestinal absorption by enterocytes, transport of iron in plasma bound to transferrin, cellular uptake via transferrin receptors, intracellular storage in ferritin, and systemic regulation by the peptide hormone hepcidin, which controls iron export through ferroportin. Serum ferritin reflects body iron stores but may be altered by inflammation, liver disease, or malignancy and thus requires contextual interpretation.

Policy Summary

PayerCapital Bluecross

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism

Change TypeMinor/No material change

Effective Date

Next Review DateMay 1, 2026

Key ActionOrder serum ferritin or transferrin saturation only when indications listed in the coverage criteria are met and document clinical rationale in the record.

SourceLink

On This Page

General iron deficiency cutoffFerritin <30 µg/L commonly used to define absolute iron deficiency in general populations.

AGA and guideline variationsGuideline sources (eg, AGA, ICCAMS, ECCO) describe higher ferritin thresholds in inflammatory states and practical monitoring intervals; specific recommendations vary by society and clinical context.

Ferritin and TSAT thresholds — inv-20

Absolute iron deficiencyFerritin <30 ng/mL and/or TSAT <20% indicate absolute iron deficiency.

Inflammatory states/CKD adjustmentFerritin <100 ng/mL may define iron deficiency in inflammatory states; KDIGO and other guidelines recommend using TSAT with ferritin to guide therapy in CKD.

RLS treatment thresholdsFor restless legs syndrome, supplementation is suggested if ferritin ≤75 ng/mL or TSAT <20%; IV iron may be considered when ferritin 75–100 ng/mL per AASM guidance.

Physiologically based serum ferritin thresholds — inv-21

Physiologically based thresholds referencedPhysiologically based serum ferritin thresholds are referenced (Lancet Haematol study) but exact numeric cutoffs are not provided in the cited chunks.

Source studyReference to a NHANES-based Lancet Haematology analysis of physiologically based ferritin thresholds (Phillips et al./Mei et al. series).

Use cautionDocument notes that physiologically derived thresholds are discussed in the literature but specific numeric values are not included in this policy excerpt.

Preferred oral regimen: every-other-day dosing; consider vitamin C to improve absorption.
IV iron indication: intolerance to oral iron, lack of ferritin response after trial, malabsorption, post-bariatric surgery, active inflammatory bowel disease with compromised absorption.
IV product preference: formulations that achieve replacement in 1–2 infusions are preferred; document rationale for multi-infusion regimens.
Required documentation for IV iron: evidence of prior oral trial (dose/duration), intolerance or absorption issue, and laboratory response.
Reference: AGA Clinical Practice Update on Management of Iron Deficiency Anemia (2024).

Billing Rule

Procedure codes and laboratory coding/billing guidance

Procedure codes are provided for laboratory and proprietary tests as a reference. Include these codes on claims and supporting documentation per usual billing practice. Note that inclusion of codes in this policy is for reference and may not be exhaustive.

CPT/HCPCS examples: 82728 (Ferritin), 83540 (Iron), 83550 (Iron binding capacity), 84466 (Transferrin), 84999 (Unlisted chemistry).
Proprietary / proprietary LDT codes: 0024U (GlycA, NMR), 0251U (Hepcidin-25, ELISA).
Labs performing LDTs must follow CLIA validation requirements for high-complexity testing; maintain validation documentation.

Note

Prior authorization and government policy precedence

No specific prior authorization requirements are specified in this policy section. Providers should verify member benefit coverage and any payer- or plan-specific prior authorization rules separately. If there is a conflict with applicable government policies (LCDs/NCDs) those government policies take precedence.

This policy excerpt does not state a prior authorization requirement; check member benefits for plan-level PA rules.
In case of conflict with Medicare/Medicaid policy (LCD/NCD or state Medicaid), the government policy governs the determination.

Denial Risk

Ferritin interpretation in inflammatory states and CKD

Ferritin interpretation can be confounded by inflammatory states and chronic kidney disease. Use ferritin cutoffs recommended by specialty guidelines (e.g., AGA) and consider adjunct tests such as C-reactive protein, transferrin saturation, or soluble transferrin receptor when inflammation or CKD is present to avoid misclassification of iron status.

AGA: consider cutoff of 45 ng/mL (rather than 15 ng/mL) in patients with anemia; in inflammatory conditions or CKD, use additional labs (CRP, transferrin saturation, sTfR) to assess iron deficiency.
Failure to account for inflammatory markers or CKD may lead to inappropriate diagnosis and management.

Documentation Required

Laboratory validation, assay documentation, and coding

Laboratory-developed tests (LDTs) such as proprietary hepcidin or GlycA assays are regulated under CLIA as high-complexity tests and must be validated by the performing laboratory. Maintain and provide validation documentation (method validation, performance characteristics) for LDTs when requested.

LDTs are not FDA-cleared/approved for clinical use but are regulated by CMS under CLIA '88 as high-complexity tests.
Labs must retain validation records for assays (e.g., ELISA, LC-MS/MS methods for hepcidin) and make them available if requested.

Denial Risk

Tests not meeting coverage criteria / denial triggers

Tests specifically called out as not meeting coverage criteria in this policy include serum hepcidin immunoassays and GlycA testing for measuring or monitoring transferrin or other glycosylated proteins. Requests for these tests will be denied under the policy's coverage criteria. For all other non-covered scenarios, documentation should demonstrate medical necessity per the indications listed.

Not covered per policy: serum hepcidin testing (including immunoassays) and GlycA testing for transferrin/glycosylated proteins.
Denial risk: requests for these tests lack supporting evidence as required by this policy and will be managed accordingly.

By degrading ferroportin, hepcidin reduces cellular iron export leading to decreased serum iron availability and intracellular iron accumulation.

Clinical relevanceHepcidin levels reflect iron regulation and may aid diagnosis in inflammatory states, but assays and clinical utility remain under study.

Transferrin saturation (TSAT) — inv-41

DefinitionTransferrin saturation (TSAT) is the percentage of transferrin binding sites occupied by iron and is used to evaluate iron availability and overload.

Clinical interpretationLow TSAT (<20%) supports iron deficiency; high TSAT (eg, >85%) is associated with non-transferrin-bound iron and risk for extrahepatic iron accumulation.

Use with ferritinTSAT is commonly used alongside ferritin to differentiate absolute iron deficiency from inflammation-driven changes in ferritin; certain guidelines require TSAT <20% to confirm deficiency when ferritin is 100–300 µg/L.

Hepcidin assays — inv-43

ELISA vs LC-MS/MSHepcidin can be measured by competitive ELISA assays (which correlate with LC-MS/MS but may cross-react with hepcidin-20/-22) and by LC-MS/MS or HPLC/MS/MS methods with low intra-/inter-day variability.

Assay performanceValidated LC-MS/MS/HPLC-MS/MS methods report low coefficients of variation (<3–6%) and acceptable error rates, supporting higher analytical precision than some immunoassays.

Documentation implicationsAssay methodology and validation may be required when reporting specialized hepcidin testing; however, hepcidin testing does not meet coverage criteria per this policy in routine use.

GlycA — inv-44

DefinitionGlycA (glycoprotein acetylation) is an NMR-derived composite biomarker of chronic inflammation reflecting signals from multiple glycoproteins.

LimitationsBecause GlycA represents overlapping NMR signals from several glycoproteins, it cannot resolve or quantify individual protein concentrations such as transferrin.

Clinical utilityGlycA has lower imprecision than hsCRP in some studies but is not suitable for measuring transferrin specifically and does not meet coverage for that use in this policy.

Ferritin — inv-45

Ferritin as a metricFerritin is commonly used to assess iron stores and is sensitive and specific for absolute iron deficiency when interpreted in appropriate clinical context.

Interpretive limitationsAs an acute-phase reactant ferritin may be elevated in inflammation or liver disease, limiting its specificity for iron deficiency without adjunct testing.

Practical useGuidelines recommend combining ferritin with TSAT (and sometimes reticulocyte Hb or hepcidin when available) to improve diagnostic accuracy in inflammatory conditions.